Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Prestige Brands First Quarter Profit Tops Analysts’ Estimates

By Pharmaceutical Processing | August 1, 2013

Prestige Brands Holdings Inc. said Thursday that its fiscal first-quarter net income rose 41 percent from prior-year results that were weighed down by acquisition-related costs.

For the period ended June 30, Prestige —which distributes over-the-counter items like Clear Eyes and PediaCare as well as household cleaning products — earned $20.7 million, or 40 cents per share. That’s up from $14.7 million, or 29 cents per share, a year earlier.

Analysts polled by FactSet expected earnings of 38 cents per share.

The Tarrytown, N.Y., company said that the year-ago results were 35 cents per share when stripping out costs tied to the acquisition of some GlaxoSmithKline PLC brands.

Last year Prestige paid $660 million to buy 17 over-the-counter product brands from GlaxoSmithKline, including the Beano, Gaviscon and Tagamet gastrointestinal brands, BC and Goody’s pain relievers, and Sominex sleep aids.

Revenue fell 3 percent to $143 million from $147 million as it sold off the Phazyme gas treatment brand that was part of the GlaxoSmithKline deal. Wall Street was looking for $146.4 million in revenue.

Prestige anticipates full-year revenue of about $638 million to $643 million. This accounts for its acquisition of Australian over-the-counter health care products company Care Pharmaceuticals. Analysts predict full-year revenue of $633.3 million.

Its shares closed at $33.91 on Wednesday.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE